Breast lumps medical therapy
|
Breast lumps Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Breast lumps medical therapy On the Web |
|
American Roentgen Ray Society Images of Breast lumps medical therapy |
|
Risk calculators and risk factors for Breast lumps medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shadan Mehraban, M.D.[2]
Overview
Management and medical therapy of breast lumps depends on women's age (age> 40 or age <40) and mammography results in women aged > 40 years. In women aged > 40 years; no further evaluation is needed in case of clearly benign mass in mammography; however, ultrasound imaging is required for the rest of the findings mammography. Approach to breast lumps in women >40 years is depended on breast imaging reporting and data systems (BI-RADS) stages. Medical therapy of breast lumps in women< 40 years is depended on ultrasound results and BI-RADS categories.
Breast lumps medical therapy
Management of breast lumps:
- women aged >40 years with palpable mass:[1]
- Diagnostic mammography is considered as the first step.
- If the last screening test is related to more than previous 6 months, both breast mammography is required to rule out occult malignancy.
- No further evaluation is needed in case of clearly benign mass in mammography.
- Ultrasound imaging is required for the rest of cases appeared in mammography.
- Stereotactic biopsy is recommended in negative ultrasound findings addition to suspicious mammographic results.
- Women aged< 40 years with palpable mass:[2][3]
- Ultrasound or mammography is suggested for initial management of women aged between 30 to 39 years.
- Ultrasound is the first step for women< 30 years presenting with palpable mass.
Approach to breast lumps in women aged >40 years based on mammographic results:[1]
- If mammographic results become negative, the next step is targeted ultrasound.
- Negative ultrasound results considered as breast imaging reporting and data system (BI-RADS) 1, then clinical follow-up is needed.
- Benign ultrasound results considered as BI-RADS 2, then clinical follow-up is needed.
- Probably benign results considered as BI-RADS 3, then ultrasound short interval follow-up is needed.
- Suspicious ultrasound results considered as BI-RADS 4 or 5, then core-needle biopsy is needed.
- If mammographic results show only fatty tissue:
- Considered as BI-RADS 1, then clinical follow-up is needed.
- If mammographic results show benign mass:
- Considered as BI-RADS 2, then clinical follow-up
- If mammographic results are in favor of probably benign lumps, the next step is targeted ultrasound.
- Negative ultrasound results considered as BI-RADS 3, then mammographic short interval follow-up is required.
- Benign ultrasound results considered as BI-RADS 2, then clinical follow-up is required.
- Probably benign ultrasound results considered as BI-RADS 3, then ultrasound short interval follow-up.
- Suspicious ultrasound results is considered as BI-RADS 4 or 5, then core needle biopsy is required.
- If mammographic result is in favor of suspicious lesion, the next step is ultrasound to determine biopsy plan.
- Considered as BI-RADS 4 or 5, then core needle biopsy is required.
Approach to breast lumps in women aged <40 years based on targeted ultrasound findings:[1]
- If ultrasound results become negative, there are two approaches:
- Considered as BI-RADS 1, then clinical follow-up is required.
- Perform diagnostic mammography:
- Negative results are in favor of BI-RADS 1, then clinical follow-up is required.
- Benign results are considered as BI-RADS 2, then clinical follow-up is required.
- Probably benign results considered as BI-RADS 3, Mammographic short interval follow-up is required.
- Suspicious results considered as BI-RADS 4 or 5, then core needle biopsy is required.
- If ultrasound results show benign findings:
- Considered as BI-RADS 2, then clinical follow-up is required.
- If ultrasound results show probably benign findings:
- Considered as BI-RADS 3, then short interval follow-up is required.
- If ultrasound results become suspicious:
- Considered as BI-RADS 4 or 5, then core needle biopsy is required.
| Women age > 40 years | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Mammographic findings | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | Fatty tissue | Benign | Probably benign | Suspicious | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Ultrasound | BI-RADS 1, then clinical follow-up | BI-RADS 2, then clinical follow-up | Ultrasound | Ultrasound for biopsy plan determination | |||||||||||||||||||||||||||||||||||||||||||||||||||
| BI-RADS 4 or 5, then core needle biopsy | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative | Benign | Probably benign | Suspicious | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| BI-RADS 3, then mammographic short interval follow-up | BI-RADS 2, then clinical follow-up | BI-RADS 3, then ultrasound short interval follow-up | BI-RADS 4 or 5, then core needle biopsy | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Negative results | Benign | Probably benign | Suspicious | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| BI-RADS 1, then clinical follow-up | BI-RADS 2, then clinical follow-up | BI-RADS 3, then ultrasound short interval follow-up | BI-RADS 4 or 5, then core needle biopsy | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Women age < 40 years | |||||||||||||||||||||||||||||||||||||||||||||
| Targeted ultrasound | |||||||||||||||||||||||||||||||||||||||||||||
| Negative | Benign | Probably benign | Suspicious | ||||||||||||||||||||||||||||||||||||||||||
| BI-RADS 2, then clinical follow-up | BI-RADS 3, then short interval follow-up | BI-RADS 4 or 5, then core needle biopsy | |||||||||||||||||||||||||||||||||||||||||||
| BI-RADS 1, then clinical follow-up | Perform diagnostic mammography | ||||||||||||||||||||||||||||||||||||||||||||
| Negative | Benign | Probably benign | Suspicious | ||||||||||||||||||||||||||||||||||||||||||
| BI-RADS 1, then clinical follow-up | BI-RADS 2, then clinical follow-up | BI-RADS 3, Mammographic short interval follow-up | BI-RADS 4 or 5, then core needle biopsy | ||||||||||||||||||||||||||||||||||||||||||
References
- ↑ 1.0 1.1 1.2 Harvey JA, Mahoney MC, Newell MS, Bailey L, Barke LD, D'Orsi C; et al. (2016). "ACR Appropriateness Criteria Palpable Breast Masses". J Am Coll Radiol. 13 (11S): e31–e42. doi:10.1016/j.jacr.2016.09.022. PMID 27814822.
- ↑ Lehman CD, Lee AY, Lee CI (2014). "Imaging management of palpable breast abnormalities". AJR Am J Roentgenol. 203 (5): 1142–53. doi:10.2214/AJR.14.12725. PMID 25341156.
- ↑ Loving VA, DeMartini WB, Eby PR, Gutierrez RL, Peacock S, Lehman CD (2010). "Targeted ultrasound in women younger than 30 years with focal breast signs or symptoms: outcomes analyses and management implications". AJR Am J Roentgenol. 195 (6): 1472–7. doi:10.2214/AJR.10.4396. PMID 21098212.